Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of 2.7%. Here, we discuss the reasons for the same.

SpringWorks Therapeutics received FDA approval for Ogsiveo, its treatment for adult patients with desmoid tumors. Click here to read an analysis of SWTX stock.

Get the latest news on SpringWorks Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on SWTX performance ...

SpringWorks Therapeutics expects the EMA to rule on nirogacestat's marketing authorization for desmoid tumors in Q2 2025.

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) has received a consensus recommendation of “Hold” from the eight brokerages that are covering the stock, MarketBeat.com reports ...

SpringWorks Therapeutics (SWTX) closed the last trading session at $34.71, gaining 15.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...

A little over two months after it was announced, Germany-based life sciences firm Merck KGaA said Tuesday that it has completed its $3.9 billion acquisition of Stamford-based SpringWorks Therapeutics ...

Stifel Financial Corp reduced its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 7.7% in the 4th quarter, according to the company in its most recent 13F ...

SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SpringWorks' Gomekli wins FDA approval for NF1-related tumors, showing strong efficacy in trials. U.S. launch expected in two weeks, with EU review ongoing.